Anthem BioSciences (NSE:ANTHEM, BOM:544449) has an average rating of buy and mean price target of 879.43 Indian rupees, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) reported a slight increase in its consolidated attributable net profit to 9.21 billion Indian rupees in the fiscal fourth quarter ended March 31, against 9.03 billion rupees a year ago.Shares of the company fell over 6% in Friday's trade.Earnings per share inched up to 15.86 rupees compared with the year-ago figure of 15.56 rupees, according to a Thursday filing to the Indian stock exchanges by the pharmaceutical manufacturer.Revenue from operations in fiscal Q4 increased to 87.5 billion rupees from 83.8 billion rupees a year earlier.
Standard Chartered (HKG:2888) repurchased 773,000 shares on Thursday at an average price of 19.33 pounds sterling apiece, according to a Friday filing with the Hong Kong bourse.The British lender plans to cancel the shares, following which it will have about 2.21 billion shares in issue.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a Phase 1 clinical trial of HLX316 for injection, according to a Friday Hong Kong bourse filing.The trial is studying the effects of the drug in patients with advanced/metastatic solid tumors in Mainland China.